Form 4: Arcutis Biotherapeutics Director Keith Leonard Reports Significant Equity Grants

Arcutis Biotherapeutics, Inc. Director Keith R. Leonard reported the acquisition of 7,609 Restricted Stock Units and 20,568 stock options as part of his compensation for service.

Summary

• Keith R. Leonard, a Director at Arcutis Biotherapeutics, Inc. (ARQT), reported transactions on June 12, 2025.
• He acquired 7,609 Restricted Stock Units (RSUs) at a price of $0. These RSUs vest on the earlier of June 12, 2026 (first anniversary of grant) or immediately before the next annual meeting of stockholders, contingent on continued service. The settlement of these RSUs has been deferred.
• He also acquired 20,568 stock options at a price of $0, with an exercise price of $13.50. These options vest 100% on the earlier of June 12, 2026 (first anniversary of grant) or immediately before the next annual meeting of stockholders, contingent on continued service, and expire on June 12, 2035.
• Following these transactions, Mr. Leonard directly beneficially owns 26,435 shares of Common Stock and 20,568 Stock Options.
• Additionally, 1,750 shares of Common Stock are held indirectly by the Leonard Family Trust dated August 28, 1996, for which Mr. Leonard is a trustee.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates continued director commitment and alignment with shareholder interests through equity compensation. It's a routine filing, so not highly impactful on sentiment.

Positives

• The grant of equity awards (RSUs and stock options) aligns the director's interests with long-term shareholder value.
• The deferral of RSU settlement indicates a long-term commitment by the director.

Risks

• The value of the granted equity awards is subject to the future performance and stock price fluctuations of Arcutis Biotherapeutics, Inc.
• Vesting of both RSUs and stock options is contingent upon continued service as a director.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedules of the granted equity awards.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a non-employee director, a common practice across the biotechnology and pharmaceutical industries to align director incentives with shareholder interests and retain experienced board members. Such grants are standard components of director compensation packages.

Corporate Governance

Related Party Transactions

• 1,750 shares of Common Stock are held indirectly by the Leonard Family Trust dated August 28, 1996, of which the Reporting Person, Keith R. Leonard, is a trustee. Mr. Leonard disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The grant of equity awards to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term stock value. The deferral of RSU settlement suggests a long-term commitment from the director.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Vesting of 7,609 Restricted Stock Units on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to continued service.
• Vesting of 20,568 Stock Options on the earlier of June 12, 2026, or immediately before the next annual meeting of stockholders, subject to continued service.
• Potential future settlement of deferred RSUs.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership